COVED® NEW PRODUCT LAUNCH

2026-10-30T13:29:49+02:0023/04/2021|All articles, Product launches|

IASIS PHARMA has successfully launched COVED® to the Greek market. COVED® (Bisphosphonates, combinations) is a fixed dose combination of two active ingredients: Alendronic acid (as alendronate sodium trihydrate) (70mg) & Cholecalciferol (Vitamin D3) (5.600 I.U). COVED® 70 mg / 5,600 IU is indicated for the treatment of postmenopausal osteoporosis in women at risk of vitamin D [...]

GLUCOPLUS®1.000mg NEW 60 F.C. TABS PACKAGE

2026-10-30T13:29:49+02:0005/04/2021|All articles, Product launches|

IASIS PHARMA is pleased to announce the launch of the new 60 f.c. tabs packaging for GLUCOPLUS® 1.000mg (Metformin hydrochloride). Both GLUCOFREE® & GLUCOPLUS® (active ingredient: metformin hydrochloride) belong to the broader category of Oral Hypoglycemic Agents (OHAs) for the treatment of Type 2 Diabetes Mellitus (T2D) as first-line therapy. GLUCOFREE® is available in 850mg metformin hydrochloride, [...]

SENSIBIO 30® g. NEW PACKAGE

2026-10-30T13:29:49+02:0009/11/2020|All articles, Product launches|

IASIS PHARMA, consistently aware of its responsibility to serve at the highest possible level both health care professionals and patients, introduces to the pharmaceutical market Sensibio® in 30 g. new package. Sensibio® 30 g. new package was launched to the market in order to complete Sensibio® 15 g., the well-established fixed combination of Fusidic acid (antibiotic) and [...]

FLUSTERIX® 30 g. NEW PACKAGE

2026-10-30T13:29:49+02:0009/11/2020|All articles, Product launches|

IASIS PHARMA, consistently aware of its responsibility to serve at the highest possible level both health care professionals and patients, introduces to the pharmaceutical market Flusterix® in 30 g. new package. Flusterix® 30 g. was launched in order to complete the, well-established to the pharmaceutical market, Flusterix® 15 g. package. Flusterix® has Fusidic acid as its active ingredient, [...]

GLUCOFREE® & GLUCOPLUS® NEW PRODUCTS LAUNCH

2026-10-30T13:29:51+02:0004/06/2019|All articles, Product launches|

IASIS PHARMA proudly announces the addition of Glucofree® & Glucoplus® to its wide product portfolio. Glucofree® & Glucoplus® have metformin hydrochloride as their active ingredient and they belong to OHAs (Oral Hypoglycemic Agents). Metformin’s therapeutic indication is type 2 diabetes, especially on obese patients when the imposed diet and body exercise are not enough to [...]

MAG-IASIS® NEW PRODUCT LAUNCH

2026-10-30T13:29:52+02:0022/01/2018|All articles, Product launches|

IASIS PHARMA announces the launch of MAG-IASIS®, the first uniquely effective combination indicated for magnesium deficiency in the form of effervescent tablets. Each effervescent tablet of MAG-IASIS® contains: 1193.57 mg magnesium citrate & 667.56 mg magnesium aspartate equivalent to 243 mg Magnesium. MAG-IASIS® main indications are: ● magnesium deficiency, under the condition that it cannot [...]

ZALEPIN® RAPID NEW PRODUCT LAUNCH

2026-10-30T13:29:53+02:0003/01/2018|All articles, Product launches|

IASIS PHARMA has launched a new pharmaceutical product under the brand name of ZALEPIN® RAPID, enriching its CNS product portfolio. ZALEPIN® RAPID contains Olanzapine as its active ingredient and belongs to the class of atypical antipsychotic agents, the newer generation of antipsychotics. ZALEPIN® RAPID is available in the form of orodispersible tablets (ODT), offering the [...]

RAMI-AMLO® NEW PRODUCT LAUNCH

2026-10-30T13:29:54+02:0015/03/2017|All articles, Product launches|

IASIS PHARMA announces the launch of the original antihypertensive pharmaceutical product under the brand name of Rami-Amlo®. The product is a fixed-dose combination of an Angiotensin Converting Enzyme (ACE) Inhibitor with a Calcium Channel Blocker. Each Rami-Amlo® capsule, contains the active ingredients Ramipril & Amlodipine, combined in a single dosage form, in 4 strengths: 5mg [...]

LICOSIL PRESS RELEASE

2026-10-30T13:29:55+02:0008/09/2014|All articles, Product launches|

Pharma Q, a member of IASIS PHARMA group of companies, has launched a new pharmaceutical product under the brand name Licosil (Sildenafil) to treat erectile dysfunction. Licosil is the 1st generic sildenafil, which has been successfully launched in the Greek pharmaceutical market by a Greek pharmaceutical industry in τwο strengths: 50 and 100 mg respectively [...]

Go to Top